Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Cristina Cruz Zambrano"'
Autor:
Cristina Cruz Zambrano, Susana Bezares, Juan de la Haba, Barbara Adamo, Santiago Gonzalez Santiago, Raquel Andrés, Montserrat Muñoz, Sonia Alonso Soler, Vanesa García, M Melé, Federico Rojo, Sebastian Moran Salama, Nuria Martin, M. J. Escudero, Manel Esteller, Sonia Servitja, Sara López-Tarruella, Rosalia Caballero, Jose Alejandro Perez-Fidalgo, Angel Guerrero-Zotano
Publikováno v:
Journal of Clinical Oncology. 36:TPS1114-TPS1114
TPS1114Background: Identification of targeted therapies for advanced triple negative breast cancer (TNBC) remains as an important clinical challenge. TNBC frequently shows BRCA dysfunction and 80% ...
Autor:
Neeltje Steeghs, Heike Richly, Maria Alsina, Roger von Moos, Peggy De Mesmaeker, Cristina Cruz Zambrano, Jordi Rodon Ahnert, Martin Schuler, Jesus Corral Jaime, Vincent Duval, Alex Morozov, Fabienne Baffert, David Demanse, Dagmar Hess, Catherine Herremans, Ahmad Awada, Luis Paz-Ares, Luc Dirix, Markus Joerger, Jean-Pascal Machiels
627^ Background: Preclinical data show PI3K-pathway inhibition can enhance the efficacy of anticancer therapy, such as PTX or TZ. In this 4-arm Ph Ib study (NCT01285466), buparlisib (pan-PI3K inhib...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2fff465cc2b8d2c6eee98468680a138
Autor:
Ana Maria Martinez de Castro, Paolo Nuciforo, Irene Brana, Ana Vivancos, Cinta Hierro, Cristina Saura, Ana Oaknin, Jordi Rodon Ahnert, Maria Ochoa de Olza, Rodrigo Dienstmann, Juan Martin Liberal, Analia Azaro, Cristina Cruz Zambrano, Josep Tabernero, Mafalda Oliveira, Helena Aguilar, Guillem Argiles, Elena Sanchez
Publikováno v:
Journal of Clinical Oncology. 34:2572-2572
2572Background: Drugs targeting aberrations in the PAM pathway are in clinical development but it is not completely clear if mut and ttx matching increases chances of ClinBen. Methods: Retrospectiv...
Autor:
Priti S. Hegde, Joseph Kim, Thomas Powles, Cristina Cruz Zambrano, Jean-Marie Bruey, Daniel P. Petrylak, Fadi Braiteh, Nicholas J. Vogelzang, Joaquim Bellmunt, Yohann Loriot, Oyewale O. Abidoye, Siew-leng Melinda Teng, Howard A. Burris
Publikováno v:
Journal of Clinical Oncology. 33:4501-4501
4501 Background: PD-L1 may contribute to immune escape in UBC, a disease of high mutational complexity and immunogenicity. MPDL3280A was designed to restore T cell–mediated antitumor activity by bl...
Autor:
Zachary Boyd, Daniel P. Petrylak, Joseph Kim, Xiaodong Shen, Yohann Loriot, Jean-Marie Bruey, Nicholas J. Vogelzang, Siew-leng Melinda Teng, Howard A. Burris, Priti S. Hegde, Joaquim Bellmunt, Thomas Powles, Cristina Cruz Zambrano
Publikováno v:
Journal of Clinical Oncology. 33:297-297
297 Background: Metastatic urothelial bladder cancer (UBC) is a mutationally-complex disease in which PD-L1 expression in the tumor microenvironment may inhibit immune-mediated antitumor responses. MPDL3280A is a PD-L1-targeting antibody with an engi
Autor:
Cinta Hierro, Ana Vivancos, Jordi Rodon, Enrique Sanz-Garcia, Marta Vilaro, D. Moreno, Santiago Ramón y Cajal, Guillem Argiles, Analia Azaro, Teresa Macarulla, José Antonio Jiménez, Cristina Cruz Zambrano, Javier Hernández-Losa, Paolo Nuciforo, Maria Alsina, Josep Tabernero, Stefania Landolfi, Tamara Sauri, Jaume Capdevila, Elena Elez
Publikováno v:
Journal of Clinical Oncology. 33:587-587
587 Background: BRAF mutation (mt) occurs in 5-8% of mCRC and its role as a negative prognostic factor is well known. The up-front detection of BRAF mt is not standardized beyond the boundaries of research. However, since novel emerging specific ther
Autor:
Thomas Powles, Xiaodong Shen, Siew-leng Melinda Teng, Priti S. Hegde, Daniel P. Petrylak, Gregg Fine, Yohann Loriot, Cristina Cruz Zambrano, Hartmut Koeppen, Daniel S. Chen, Howard A. Burris, Joaquim Bellmunt, Joseph Paul Eder, Nicholas J. Vogelzang, Fadi Braiteh
Publikováno v:
Journal of Clinical Oncology. 32:5011-5011
5011 Background: Metastatic UBC is associated with a poor prognosis and limited treatment options. PD-L1 expression is prevalent in this disease and may protect cancer cells from immune-mediated de...
Autor:
Khaldoun Almhanna, Jordi Rodon Ahnert, Adedigbo Fasanmade, Tim Wyant, Cristina Cruz Zambrano, Jason E. Faris, Wells A. Messersmith, Thea Kalebic, JungAh Jung, David P. Ryan
Publikováno v:
Journal of Clinical Oncology. 32:3546-3546
3546 Background: This first-in-human study (NCT01577758) assessed the safety and tolerability, dose limiting toxicities (DLTs), maximum tolerated dose (MTD), pharmacokinetics, and preliminary antit...
Autor:
Neeltje Steeghs, Maria Alsina, Catherine Herremans, Peggy De Mesmaeker, Ahmad Awada, Heike Richly, Fabienne Baffert, Roger von Moos, Cristina Cruz Zambrano, Martin Schuler, Dagmar Hess, Luc Dirix, David Demanse, Markus Joerger, Jean-Pascal Machiels, Alex Morozov, Luis Paz-Ares, Jesus Corral Jaime, Vincent Duval, Jordi Rodon Ahnert
Publikováno v:
Journal of Clinical Oncology. 32:621-621
621^ Background: Preclinical data suggest BEZ235 (BEZ; dual PI3K/mTOR inhibitor) may enhance the activity of PTX ± TZ in pts with advanced cancers. In this 4-arm study (NCT01285466), BEZ or buparli...
Autor:
Marta Vilaro, Maria Alsina, Ana Vivancos, Jordi Rodon, Ana Oaknin, Teresa Macarulla, Paolo Nuciforo, Ana C. Garrido-Castro, B. Adamo, José Antonio Jiménez, Alba Meire, Analia Azaro, Victor Rodriguez-Freixinos, Cristina Cruz Zambrano, D. Moreno, Jose Maria Del Campo, Guillem Argiles, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 32:5578-5578
5578 Background: In the wake of personalized medicine in Oncology, genetic tumor profiling has become a cornerstone to select patients (pts) for clinical trials, exploring new molecular targeted ag...